<DOC>
	<DOCNO>NCT00568750</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well dasatinib work first-line therapy treat patient gastrointestinal stromal tumor .</brief_summary>
	<brief_title>Dasatinib First-Line Therapy Treating Patients With Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine efficacy dasatinib assess fusion PET/CT scan patient gastrointestinal stromal tumor . Secondary - To determine efficacy safety dasatinib patient . - To correlate efficacy dasatinib KIT PDGFR mutational status . - To correlate efficacy safety dasatinib dasatinib drug exposure . - To determine efficacy second-line treatment another TK-inhibitor . OUTLINE : This multicenter study . Patients receive oral dasatinib twice daily day 1-28 . Treatment repeat every 28 day 26 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 4 year .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastrointestinal stromal tumor ( GIST ) Measurable disease conventional scan ( CT scan MRI ) within 2 week prior study registration Positive PET/CT scan [ ^18F ] fluorodeoxyglucose uptake target lesion within 2 week prior study registration No sign history CNS metastases PATIENT CHARACTERISTICS : WHO performance status 02 Hemoglobin ≥ 90 g/L ( transfusion allow ) Neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Bilirubin ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN AST and/or ALT ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study therapy No malignancy within past 5 year except adequately treat carcinoma situ cervix localize nonmelanoma skin cancer No hypocalcemia ( i.e. , serum calcium ≤ low limit normal ) No clinically significant cardiovascular disease , include follow : Uncontrolled hypertension Congestive heart failure within past 6 month QTc &gt; 450 msec major conduction abnormality ( unless cardiac pacemaker present ) No concurrent medical condition ( e.g. , active autoimmune disease uncontrolled diabetes ) would impair ability patient participate study ( judgment investigator ) may increase risk toxicity , include follow : Pleural pericardial effusion grade Clinically significant coagulation platelet function disorder ( e.g. , know von Willebrand 's disease ) Infection require intravenous antibiotic Ongoing significant gastrointestinal bleeding Nausea , vomiting , malabsorption syndrome could interfere ingestion absorption oral dasatinib No known hypersensitivity study drug PRIOR CONCURRENT THERAPY : No prior therapy GIST , particularly tyrosine kinase inhibitor time More 30 day since prior participation clinical trial At least 7 day since prior concurrent potent CYP3A4 inhibitor , include follow : Itraconazole , ketoconazole , miconazole , voriconazole Amprenavir , atazanavir , fosamprenavir , indinavir , nelfinavir , ritonavir Ciprofloxacin , clarithromycin , diclofenac , doxycycline , enoxacin , imatinib mesylate , isoniazid , ketamine , nefazodone , nicardipine , propofol , quinidine , telithromycin At least 7 day since prior concurrent medication know prolong QT interval , include follow : Quinidine , procainamide , disopyramide , amiodarone , sotalol , ibutilide , dofetilide Erythromycin clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide Cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine No concurrent IV bisphosphonates first 8 week study treatment No concurrent experimental drug anticancer therapy No concurrent drug contraindicate use dasatinib , accord dasatinib investigator 's brochure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gastrointestinal stromal tumor</keyword>
</DOC>